Lars Edvinsson
Founder, CSO and board member
Professor Edvinsson is a leading expert in the field of cerebral circulation. He is world-recognized for his work on vascular innervation and receptor regulation. His extensive research is a major contributor to the current knowledge about the roles of the cerebral vasculature in health and diseases such as stroke and primary headaches. He is the director and founder of the Glostrup Science Park at Copenhagen University Hospital and Professor in Internal Medicine, Faculty of Medicine, and senior consultant in internal medicine, University Hospital SUS Lund. He has received numerous honors and awards including Director and President, International Headache Society; Member, Steering Board, European Headache Federation; Honorary Doctorate, University of Xián, China; Lifetime Achievement Award, American Headache Society. He was recently awarded the Lundbeck Foundation’s prestigious Brain Prize 2021. He is a citizen of Sweden.
Tore Duvold
CEO and board member
Dr. Duvold holds a PhD degree in chemistry from Université Louis Pasteur. He has extensive experience in the biotech and the pharmaceutical industries including SVP and head of research, early development and patent at LEO Pharma, CEO and co-founder of Aker Biopharma, CEO of Coegin Pharma. He recently served as EVP and later CEO of Innovation Fund Denmark. Dr. Duvold is also associated partner at Copenhagen Institute for Futures Studies and has comprehensive experience in university collaborations and has served as advisor for University of Copenhagen and the Technical University of Denmark. He is a citizen of Norway and Denmark.
Stine Larsen
Chief Medical Officer
Dr. Larsen holds a PhD in neurobiology, and has 10 years of experience in drug discovery as well as 15 years of experience in drug development from Lundbeck, ALK and Klifo. She has primarily worked within the field of neurodegenerative disorders in both drug discovery and drug development, with experience throughout the whole value chain from target discovery to filing a market authorization application, including experience in Phase I, II, and III. At ALK, Stine developed and executed a large pediatric study in allergic asthma. At Klifo, she was the head of the Pharmacovigilance Department. Stine Larsen’s passion is to use her molecular understanding of disease biology and the drug being tested as the basis for designing clinical development programs, with a view to highlighting drug efficacy. She is a citizen of Denmark.